(NASDAQ: MDXG) Mimedx Group's forecast annual revenue growth rate of 3.8% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.11%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.55%.
Mimedx Group's revenue in 2026 is $355,173,000.On average, 7 Wall Street analysts forecast MDXG's revenue for 2026 to be $40,114,738,398, with the lowest MDXG revenue forecast at $37,282,612,505, and the highest MDXG revenue forecast at $42,088,335,135. On average, 7 Wall Street analysts forecast MDXG's revenue for 2027 to be $48,991,550,899, with the lowest MDXG revenue forecast at $41,567,970,264, and the highest MDXG revenue forecast at $67,678,042,897.
In 2028, MDXG is forecast to generate $57,903,345,913 in revenue, with the lowest revenue forecast at $47,994,549,298 and the highest revenue forecast at $74,305,771,377.